Literature DB >> 23249225

Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever.

Olga Lihoradova, Tetsuro Ikegami.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23249225      PMCID： PMC4722535          DOI： 10.1586/erv.12.106

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


× No keyword cloud information.
  19 in total

1.  Creation of a nonspreading Rift Valley fever virus.

Authors:  Jeroen Kortekaas; Nadia Oreshkova; Viviana Cobos-Jiménez; Rianka P M Vloet; Christiaan A Potgieter; Rob J M Moormann
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 3.  Molecular biology and genetic diversity of Rift Valley fever virus.

Authors:  Tetsuro Ikegami
Journal:  Antiviral Res       Date:  2012-06-16       Impact factor: 5.970

4.  Replication of Clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, in Aedes and Culex mosquitoes.

Authors:  Sara Moutailler; Ghazi Krida; Yoann Madec; Michèle Bouloy; Anna-Bella Failloux
Journal:  Vector Borne Zoonotic Dis       Date:  2010-10       Impact factor: 2.133

5.  Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep.

Authors:  Brian H Bird; Louis H Maartens; Shelley Campbell; Baltus J Erasmus; Bobbie R Erickson; Kimberly A Dodd; Christina F Spiropoulou; Deborah Cannon; Clifton P Drew; Barbara Knust; Anita K McElroy; Marina L Khristova; César G Albariño; Stuart T Nichol
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

6.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

7.  The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.

Authors:  Olga Lihoradova; Birte Kalveram; Sabarish V Indran; Nandadeva Lokugamage; Terry L Juelich; Terence E Hill; Chien-Te K Tseng; Bin Gong; Shuetsu Fukushi; Shigeru Morikawa; Alexander N Freiberg; Tetsuro Ikegami
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

Review 8.  The pathogenesis of Rift Valley fever.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Viruses       Date:  2011-05       Impact factor: 5.048

9.  Molecular epidemiology of Rift Valley fever virus.

Authors:  Antoinette A Grobbelaar; Jacqueline Weyer; Patricia A Leman; Alan Kemp; Janusz T Paweska; Robert Swanepoel
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

10.  Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection.

Authors:  Mary B Crabtree; Rebekah J Kent Crockett; Brian H Bird; Stuart T Nichol; Bobbie Rae Erickson; Brad J Biggerstaff; Kalanthe Horiuchi; Barry R Miller
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01
View more
  5 in total

Review 1.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

2.  Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.

Authors:  Shoko Nishiyama; Olga A L Slack; Nandadeva Lokugamage; Terence E Hill; Terry L Juelich; Lihong Zhang; Jennifer K Smith; David Perez; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  Virulence       Date:  2016-06-01       Impact factor: 5.882

3.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

4.  Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative of severe disease.

Authors:  Petrus Jansen van Vuren; Sharon Shalekoff; Antoinette A Grobbelaar; Brett N Archer; Juno Thomas; Caroline T Tiemessen; Janusz T Paweska
Journal:  Virol J       Date:  2015-10-06       Impact factor: 4.099

Review 5.  Temperature-sensitive mutations for live-attenuated Rift Valley fever vaccines: implications from other RNA viruses.

Authors:  Shoko Nishiyama; Tetsuro Ikegami
Journal:  Front Microbiol       Date:  2015-08-11       Impact factor: 5.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.